secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2021-09-23T23:59:59+00:00
Accession:  0001193125-21-279962
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences reports SGT-001 1.5-year data showing functional benefit in DMD patients 4-6
--------------------------------------------------------------------------------

- NSAA mean decrease 1.7 pts vs expected 4.5 pt decline from natural history; difference +2.8 pts.
- 6MWT mean increase 15.3 meters vs expected 63.5-meter decline; difference +78.8 meters.
- Percent predicted FVC improved 4.1% vs expected 7.5% decline; difference +11.6%.
- PODCI global, sports, transfer, upper-body scales showed sustained improvements at 1.5 years.
- No new drug-related safety findings in patients with post-dosing periods up to 3.5 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312521279962/0001193125-21-279962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312521279962/d200279d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-279962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer